Metabolic Dysfunction Associated Steatohepatitis Mash clinical trials

Explore recruiting metabolic dysfunction associated steatohepatitis mash clinical trials.

Recruiting metabolic dysfunction associated steatohepatitis mash studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metabolic Dysfunction Associated Steatohepatitis Mash trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Belgium, Greece, Poland, France, Spain, Bulgaria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Greece, Germany, Belgium, Netherlands, Poland, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Spain, Poland, France, Italy, Bulgaria, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Spain, Hungary, Netherlands, Belgium, Bulgaria, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis

Spain, Germany, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

France, Italy, Germany, Spain, Poland, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metabolic Dysfunction Associated Steatohepatitis Mash trials by city

Metabolic Dysfunction Associated Steatohepatitis Mash in Toronto Metabolic Dysfunction Associated Steatohepatitis Mash in Vancouver Metabolic Dysfunction Associated Steatohepatitis Mash in Montreal Metabolic Dysfunction Associated Steatohepatitis Mash in Calgary Metabolic Dysfunction Associated Steatohepatitis Mash in Edmonton Metabolic Dysfunction Associated Steatohepatitis Mash in Ottawa Metabolic Dysfunction Associated Steatohepatitis Mash in Winnipeg Metabolic Dysfunction Associated Steatohepatitis Mash in Quebec City Metabolic Dysfunction Associated Steatohepatitis Mash in Hamilton Metabolic Dysfunction Associated Steatohepatitis Mash in Kitchener Metabolic Dysfunction Associated Steatohepatitis Mash in London Metabolic Dysfunction Associated Steatohepatitis Mash in Halifax Metabolic Dysfunction Associated Steatohepatitis Mash in New York Metabolic Dysfunction Associated Steatohepatitis Mash in Los Angeles Metabolic Dysfunction Associated Steatohepatitis Mash in Chicago Metabolic Dysfunction Associated Steatohepatitis Mash in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease